Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Escalation Study to Assess Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) in Subjects With Uterine Leiomyoma (Fibroids)

NCT02889848 is registered in ClinicalTrials.gov with Advance Biofactures Corporation as lead sponsor.

NCT NCT02889848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02889848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Escalation Study to Assess Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) in Subjects With Uterine Leiomyoma (Fibroids)
Lead sponsor
Advance Biofactures Corporation
Phase
Phase 1
Overall status
Completed
Start date
October 27, 2016
Completion date
November 15, 2018
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibroids, uterine, leiomyoma